Sign Out
Hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or to any excipients in the desvenlafaxine formulation.
Desvenlafaxine is an inhibitor of both norepinephrine and serotonin reuptake. Desvenlafaxine succinate must not be used in combination with a monoamine oxidase inhibitor (MAOI), or within at least 14 days of discontinuing treatment with an MAOI. Based on the half-life of desvenlafaxine succinate, at least 7 days should be allowed after stopping desvenlafaxine succinate before starting an MAOI. Starting desvenlafaxine succinate in a patient who is being treated with a reversible MAOI such as linezolid or in whom intravenous methylene blue has been administered is also contraindicated because of an increased risk of serotonin syndrome (see Dosage & Administration; Precautions).
Continue with Google